By Joe Hoppe

AstraZeneca PLC said Wednesday that its Lynparza and Imfinzi combination met its endpoint in the treatment of patients with advanced ovarian cancer.

The pharma major said the combination improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without tumor BRCA mutations, in a DUO-O Phase 3 trial.

Positive high-level results from a planned interim analysis of the trial showed treatment with a combination of Lynparza, Imfinzi, chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival when compared to just chemotherapy and bevacizumab, it said.

In an additional arm, Imfinzi, chemotherapy and bevacizumab without Lynparza showed a numerical improvement in progression free survival, but didn't reach statistical significance at the interim point.

The safety and tolerability of the combinations are broadly consistent with observations from prior clinical trials and the known profiles of the medicines.

The Phase 3 trial enrolled more than 1,200 patients across all treatment arms, in a randomized, double-blind placebo-controlled test.

Write to Joe Hoppe at joseph.hoppe@wsj.com

(END) Dow Jones Newswires

April 05, 2023 02:27 ET (06:27 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Astrazeneca.